Pacira Historical Income Statement

PCRX Stock

USD 17.55 0.17 0.98%

Historical analysis of Pacira BioSciences, income statement accounts such as Gross Profit of 514.8 M, Other Operating Expenses of 616.7 M, Operating Income of 92.1 M or Ebit of 91.7 M can show how well Pacira BioSciences, performed in making a profits. Evaluating Pacira BioSciences, income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pacira BioSciences,'s future profits or losses.

Cash Flow Balance Sheet Income Statement

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Pacira BioSciences, latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pacira BioSciences, is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira BioSciences,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira BioSciences, guide.

About Pacira Income Statement Analysis

Pacira BioSciences, Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Pacira BioSciences, shareholders. The income statement also shows Pacira investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Pacira BioSciences, Income Statement Chart

At this time, Pacira BioSciences,'s Income Tax Expense is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 7.3 M in 2024, whereas Interest Expense is likely to drop slightly above 15.8 M in 2024.

Selling General Administrative Total Revenue Other Operating Expenses Research Development Net Income From Continuing Ops

Total Revenue

Total revenue comprises all receipts Pacira BioSciences, generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pacira BioSciences,. It is also known as Pacira BioSciences, overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Pacira BioSciences,'s income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pacira BioSciences, current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira BioSciences,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pacira Stock please use our How to Invest in Pacira BioSciences, guide.At this time, Pacira BioSciences,'s Income Tax Expense is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 7.3 M in 2024, whereas Interest Expense is likely to drop slightly above 15.8 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	31.8M	40.0M	20.3M	15.8M
Depreciation And Amortization	28.5M	91.5M	75.6M	79.4M

Interest Expense Depreciation And Amortization

Pacira BioSciences, income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Selling And Marketing Expenses	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.59	0.7	0.85	0.83	0.87	0.69	0.73	0.62	0.88	0.89	0.66	0.72	-0.59	0.45	0.18	0.31	-0.67	-0.42	0.67	0.06	0.05	-0.68	0.97
Interest Expense	0.59		0.82	0.79	0.8	0.77	0.77	0.76	0.86	0.75	0.75	0.9	0.63	-0.84	0.6	-0.18	0.62	-0.05	-0.02	0.85	-0.2	-0.31	-0.96	0.46
Selling General Administrative	0.7	0.82		0.87	0.87	0.87	0.78	0.78	0.92	0.81	0.85	0.94	0.75	-0.69	0.6	-0.02	0.54	-0.24	0.0	0.94	-0.09	-0.13	-0.78	0.6
Total Revenue	0.85	0.79	0.87		1.0	0.99	0.9	0.92	0.82	0.96	0.98	0.87	0.89	-0.76	0.66	0.05	0.55	-0.59	-0.18	0.92	-0.07	-0.13	-0.8	0.78
Gross Profit	0.83	0.8	0.87	1.0		0.98	0.92	0.94	0.82	0.96	0.97	0.87	0.9	-0.77	0.68	0.04	0.57	-0.58	-0.15	0.92	-0.07	-0.12	-0.81	0.76
Other Operating Expenses	0.87	0.77	0.87	0.99	0.98		0.84	0.87	0.83	0.93	0.99	0.88	0.83	-0.74	0.62	0.05	0.5	-0.6	-0.17	0.92	-0.07	-0.11	-0.77	0.81
Operating Income	0.69	0.77	0.78	0.9	0.92	0.84		0.98	0.67	0.94	0.83	0.74	0.96	-0.74	0.74	0.03	0.65	-0.49	-0.19	0.79	-0.07	-0.16	-0.81	0.59
Ebit	0.73	0.76	0.78	0.92	0.94	0.87	0.98		0.7	0.97	0.85	0.75	0.96	-0.77	0.78	-0.03	0.68	-0.56	-0.19	0.82	-0.15	-0.04	-0.79	0.66
Research Development	0.62	0.86	0.92	0.82	0.82	0.83	0.67	0.7		0.72	0.78	0.94	0.58	-0.79	0.52	-0.1	0.48	-0.18	0.1	0.93	-0.15	-0.14	-0.79	0.55
Ebitda	0.88	0.75	0.81	0.96	0.96	0.93	0.94	0.97	0.72		0.92	0.76	0.94	-0.76	0.71	0.05	0.58	-0.64	-0.29	0.82	-0.08	-0.01	-0.8	0.83
Cost Of Revenue	0.89	0.75	0.85	0.98	0.97	0.99	0.83	0.85	0.78	0.92		0.86	0.82	-0.72	0.6	0.06	0.49	-0.58	-0.27	0.88	-0.05	-0.17	-0.77	0.82
Total Operating Expenses	0.66	0.9	0.94	0.87	0.87	0.88	0.74	0.75	0.94	0.76	0.86		0.66	-0.78	0.58	-0.11	0.56	-0.15	0.02	0.97	-0.16	-0.2	-0.83	0.56
Income Before Tax	0.72	0.63	0.75	0.89	0.9	0.83	0.96	0.96	0.58	0.94	0.82	0.66		-0.59	0.77	0.02	0.65	-0.63	-0.18	0.75	-0.11	-0.03	-0.68	0.65
Total Other Income Expense Net	-0.59	-0.84	-0.69	-0.76	-0.77	-0.74	-0.74	-0.77	-0.79	-0.76	-0.72	-0.78	-0.59		-0.53	0.09	-0.5	0.22	0.2	-0.77	0.14	0.11	0.84	-0.55
Net Income	0.45	0.6	0.6	0.66	0.68	0.62	0.74	0.78	0.52	0.71	0.6	0.58	0.77	-0.53		-0.61	0.97	-0.31	-0.12	0.64	-0.71	-0.12	-0.61	0.37
Income Tax Expense	0.18	-0.18	-0.02	0.05	0.04	0.05	0.03	-0.03	-0.1	0.05	0.06	-0.11	0.02	0.09	-0.61		-0.72	-0.28	-0.03	-0.1	0.98	0.15	0.12	0.22
Net Income From Continuing Ops	0.31	0.62	0.54	0.55	0.57	0.5	0.65	0.68	0.48	0.58	0.49	0.56	0.65	-0.5	0.97	-0.72		-0.1	-0.04	0.58	-0.77	-0.22	-0.6	0.2
Non Recurring	-0.67	-0.05	-0.24	-0.59	-0.58	-0.6	-0.49	-0.56	-0.18	-0.64	-0.58	-0.15	-0.63	0.22	-0.31	-0.28	-0.1		0.31	-0.31	-0.12	-0.24	0.15	-0.74
Non Operating Income Net Other	-0.42	-0.02	0.0	-0.18	-0.15	-0.17	-0.19	-0.19	0.1	-0.29	-0.27	0.02	-0.18	0.2	-0.12	-0.03	-0.04	0.31		0.05	0.03	-0.02	0.18	-0.41
Selling And Marketing Expenses	0.67	0.85	0.94	0.92	0.92	0.92	0.79	0.82	0.93	0.82	0.88	0.97	0.75	-0.77	0.64	-0.1	0.58	-0.31	0.05		-0.18	-0.1	-0.77	0.6
Tax Provision	0.06	-0.2	-0.09	-0.07	-0.07	-0.07	-0.07	-0.15	-0.15	-0.08	-0.05	-0.16	-0.11	0.14	-0.71	0.98	-0.77	-0.12	0.03	-0.18		0.09	0.16	0.08
Interest Income	0.05	-0.31	-0.13	-0.13	-0.12	-0.11	-0.16	-0.04	-0.14	-0.01	-0.17	-0.2	-0.03	0.11	-0.12	0.15	-0.22	-0.24	-0.02	-0.1	0.09		0.36	0.23
Net Interest Income	-0.68	-0.96	-0.78	-0.8	-0.81	-0.77	-0.81	-0.79	-0.79	-0.8	-0.77	-0.83	-0.68	0.84	-0.61	0.12	-0.6	0.15	0.18	-0.77	0.16	0.36		-0.54
Reconciled Depreciation	0.97	0.46	0.6	0.78	0.76	0.81	0.59	0.66	0.55	0.83	0.82	0.56	0.65	-0.55	0.37	0.22	0.2	-0.74	-0.41	0.6	0.08	0.23	-0.54

Click cells to compare fundamentals

Pacira BioSciences, Account Relationship Matchups

Pacira BioSciences, income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	5.7M	19.9M	28.5M	91.5M	75.6M	79.4M
Interest Expense	23.6M	25.7M	31.8M	40.0M	20.3M	15.8M
Selling General Administrative	71.1M	74.8M	88.3M	109.5M	116.4M	63.1M
Total Revenue	421.0M	420.8M	541.5M	666.8M	675.0M	708.7M
Gross Profit	314.3M	303.5M	401.3M	467.5M	490.3M	514.8M
Other Operating Expenses	385.3M	378.1M	408.7M	595.9M	587.3M	616.7M
Operating Income	38.1M	46.4M	131.1M	60.0M	87.7M	92.1M
Ebit	38.1M	51.5M	89.9M	53.3M	87.3M	91.7M
Research Development	72.1M	59.4M	55.5M	84.8M	76.3M	46.7M
Ebitda	43.8M	71.4M	118.5M	144.8M	162.9M	171.0M
Cost Of Revenue	106.7M	117.3M	140.3M	199.3M	184.7M	193.9M
Total Operating Expenses	278.6M	260.8M	268.4M	396.6M	326.4M	188.9M
Income Before Tax	(10.7M)	20.1M	56.4M	13.3M	61.7M	64.8M
Total Other Income Expense Net	(48.9M)	(26.3M)	(33.5M)	(46.7M)	(26.0M)	(24.7M)
Net Income	(11.0M)	145.5M	42.0M	15.9M	42.0M	44.1M
Income Tax Expense	268K	(125.4M)	14.4M	(2.6M)	19.7M	20.7M
Net Income From Continuing Ops	(11.0M)	145.5M	42.0M	15.9M	7.0M	7.3M
Non Operating Income Net Other	5.6M	2.4M	(590K)	(1.8M)	(2.0M)	(1.9M)
Net Income Applicable To Common Shares	(11.0M)	145.5M	42.0M	15.9M	18.3M	19.2M
Selling And Marketing Expenses	129.7M	118.7M	111.0M	145.0M	153.0M	106.6M
Tax Provision	268K	(125.4M)	14.4M	(2.6M)	2.9M	3.1M
Interest Income	7.4M	4.6M	896K	4.5M	10.8M	5.8M
Net Interest Income	(16.3M)	(21.0M)	(30.9M)	(35.4M)	(17.2M)	(18.0M)
Reconciled Depreciation	19.6M	19.9M	13.6M	91.5M	87.5M	91.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pacira Historical Income Statement

About Pacira Income Statement Analysis

Pacira BioSciences, Income Statement Chart

Total Revenue

Other Operating Expenses

Pacira BioSciences, income statement Correlations

Pacira BioSciences, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pacira BioSciences, income statement Accounts

Also Currently Popular

Additional Tools for Pacira Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Other Operating Expenses	+ 0.99	Total Revenue
Cost Of Revenue	+ 0.99	Other Operating Expenses
Cost Of Revenue	+ 0.98	Total Revenue
Other Operating Expenses	+ 0.98	Gross Profit
Ebit	+ 0.98	Operating Income

Net Interest Income	- 0.96	Interest Expense
Total Other Income Expense Net	- 0.84	Interest Expense
Net Interest Income	- 0.83	Total Operating Expenses
Net Interest Income	- 0.81	Operating Income
Net Interest Income	- 0.81	Gross Profit
Net Interest Income	- 0.8	Ebitda